Although RNase Y acts as the key enzyme initiating mRNA decay in Bacillus subtilis and likely in many other Gram positive bacteria, its three-dimensional structure remains unknown. An antibody, belonging to the rare IgG2b, lx isotype, was raised against a 12-residue conserved peptide from the N-terminal non-catalytic domain of Bacillus subtilis RNase Y (BsRNaseY) that is predicted to be intrinsically disordered. Here we show that this domain can be produced 
Introduction
The processing and degradation of mRNA is a key element in the control of prokaryotic gene expression (1) (2) (3) . In E. coli, RNase E has a pivotal role in these processes (4) but Bacillus subtilis and many other Gram positive bacteria have a very different set of enzymes directing mRNA metabolism (5) (6) (7) . Indeed, in B. subtilis, a novel endoribonuclease called RNase Y (BsRNaseY) shares extensive functional homologies with RNase E despite the absence of sequence similarity (8) . Although not essential for cell viability, the crucial role of RNase Y in initiating mRNA cleavage is highlighted by deletion experiments of the rny gene, which led to defects in cell growth, cell morphology and hypersensitivity to antibiotics (9) . The abundance of a large number of transcripts is affected by decreasing RNase Y expression (8, (10) (11) (12) (13) (14) .
Consequently, the half-life of mRNA is increased two-fold when RNase Y is depleted (8) .
The three-dimensional structure of BsRNaseY is unknown but a structure prediction analysis revealed its probable architecture (12) (Figure S1 in the Supporting Material): a transmembrane (TM) region, anchoring the protein to the membrane and predicted to span residues [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] according to the TMpred server, is followed by an intrinsically disordered domain (IDD) (Figure 1 ), a catalytic domain with KH (residues 210-280) (15) and HD motifs (residues 330-430) (16) and a C-terminal region of unknown function. Although the IDD region is predicted to be highly disordered, as detected by disorder predictor programs such as IUPRED (17) ( Figure S1A ), it is also predicted to be organized mainly as a-helices by secondary structure prediction programs and to adopt a flexible coiled-coil-like structure (12) . The IDD is hypothesized to adopt various conformations to enable the protein to interact with several cellular partners (RNA or proteins), a typical behavior for intrinsically disordered proteins (18) (19) (20) (21) (22) .
Only a few in vitro studies of BsRNaseY have been reported, including activity tests (8) and ultracentrifugation experiments that showed that the main oligomeric form is a dimer (12) . To get more information about the three-dimensional structure of RNase Y, we raised an antibody against a small region of the IDD. Not only could this antibody stabilize the conformation of RNase Y, which would favor crystallization of the complex, but it could also serve to get insights into the structure/function of the IDD.
We report here the characterization of the interaction between BsRNaseY and an antibody named RY79-90 raised against a 12-residue peptide from the IDD (Figure 1 ) using ELISA (Enzyme Linked ImmunoSorbent Assay) and Size Exclusion Chromatography coupled with Multi-angle light scattering (SEC-MALS). Our results show that the antibody binds BsRNaseY with high affinity but is more specific for its N-terminal domain. We produced this domain as a stand-alone protein called Nter-BsRNaseY and characterized its structure by circular dichroism (CD) spectroscopy and Size Exclusion Chromatography coupled with Small Angle X-ray Scattering (SEC-SAXS). Nter-BsRNaseY, which displays a fast equilibrium between monomeric and dimeric forms, is bound as a monomer when complexed with the fragment antigen binding (Fab) of RY79-90. We also solved the crystal structure of Fab RY79-90 in complex with the peptide used to raise the antibody. We show that the peptide undergoes an induced folding upon binding antibody RY79-90 and discuss how the detailed interactions of the peptide/Fab complex observed in the crystal structure could mimic the binding of a microdomain of the N-terminal domain of BsRNaseY and a cellular partner.
MATERIALS & METHODS

Antibody selection
The sequence of B. subtilis RNase Y was analyzed by the Abmart Company (Shanghai, China) using the SEAL TM algorithm designed for identifying protein fragments most susceptible to yield monoclonal antibodies. Six antigen peptides, five of them contained within the IDD of B.
subtilis RNase Y, were selected for immunization. All antibodies were tested for their sensitivity and specificity to detect RNase Y in total B. subtilis cell extracts or the purified protein by Western blotting as described (23) . Briefly, cell extracts, prepared by ultrasonic disruption as reported (24) , or BsRNAseY purified by Ni-NTA chromatography were separated on a 10% SDS-PAGE gel. Monoclonal antibodies were used at a final concentration of 2 µg/ml and the signal was quantified by chemiluminescence (ECL GE Healthcare) using a horseradish peroxidase (HRP) secondary antibody conjugate (GE Healthcare). Finally, peptide 79-90 (ERRNELQKQENR) was chosen for large scale production of monoclonal antibody in mice ascitic fluid.
Production, purification and characterization of the Fab fragment
The IgG (IgG2b, lx) was produced from mice ascitic fluid, purified by Protein A affinity chromatography by Abmart Company and stored in 50 mM Tris, 100 mM Glycine pH 9, 0.5%
ProClin 300 (Sigma-Aldrich). The Fab was generated by papain digestion of the antibody at 37°C in 20 mM sodium phosphate, 274 mM NaCl, 5.4 mM KCl pH 7.4, 1.25 mM EDTA, 1.25 mM 2-mercaptoethanol using a 0.5 % papain: antibody ratio (w/w) for 5 hours. Undigested IgG and Fc fragment were removed by HiTrapQ anion exchange chromatography. The Fab was dialyzed against 200 mM NaCl, 5% glycerol and concentrated to 6.5 mg/ml.
Fab sequence determination
Sequencing of the variable heavy chain was performed by ProMab Biotechnologies Inc, Richmond, CA (USA). Total RNA was extracted from 100,000 hybridoma cells. Using PCR methods and a mixture of constant region sequences, the scFv region was amplified for cloning and sequencing. The sequence of the variable light chain could not be determined by this method, probably because of its very rare Vlx isotype, as identified during structure solving by X-ray crystallography (see below). Mass spectrometry analysis of the lower mass protein band of Fab after migration on a SDS-PAGE gel under reducing conditions confirmed that the amino acid sequences of the Fab RY79-90 light chain and Fab 13F6-1-2 (25) differ only in 3 amino acids.
Expression of Nter-BsRNaseY and BsRNaseY
The coding sequence of the rny gene from K26 to K520 (thus lacking the N-terminal transmembrane domain) was PCR-amplified from chromosomal DNA of strain SSB1002, a wild-type B. subtilis laboratory stock strain derived from strain 168, using oligonucleotides HP1182 (5'TGATTCACTCATATGAAAACCATTGCCGAAGCGAAAATTGCG3') and
HP1116
(5'AGCTAGGATCCTTAGTGATGATGATGATGGTGTTTTGCATACTCTACGGCTCGA GTC3'). The 1.5 kb PCR fragment bearing the sequence coding for the hexahistidine tag at its 3' end was inserted as an NdeI-BamHI fragment into the T7 expression vector pKYB1 plasmid (New England Biolabs) cleaved with NdeI and BglII. Recombinant plasmids from E. coli JM109 were then transformed into E. coli BL21(DE3) star codon⁺ competent cells. One colony was used to inoculate 200 ml of Luria Broth medium supplemented with kanamycine (25 µg/ml) and chloramphenicol (30 µg/ml).
For the Nter-BsRNaseY construct, the sequence corresponding to amino acids V24 to N192 of BsRNaseY appended with a C-terminal hexahistidine tag was PCR-amplified from chromosomal DNA of strain SSB1002 using the Sequence Ligation Independent Cloning method (26) . The PCR fragment was inserted as an NdeI-BamHI fragment into the T7 expression vector pET22b (New England Biolabs). The recombinant plasmid was then transformed into E. coli BL21(DE3) star codon⁺ competent cells. One colony was used to inoculate 200 ml of Luria Broth medium supplemented with ampicillin (50 µg/ml) and chloramphenicol (30 µg/ml).
Precultures (0.5% v/v) grown overnight at 37
• C at 180 rpm were used to inoculate 2 liters of LB medium supplemented with the same antibiotics. Cultures were grown at 37°C to an OD 600 of 0.8. Expression was then induced by addition of isopropyl-b-D-thiogalactopyranoside (IPTG) to a final concentration of 0.1 mM and incubation was extended overnight at 23°C.
After centrifugation for 10 min at 5000 rpm and 4°C, cells were stored at −80°C or used immediately.
Purification of Nter-BsRNaseY and BsRNaseY
Cells were resuspended in 1.5 ml/g of 20 mM HEPES pH 7.5, 500 mM NaCl, 10% glycerol 
Gel shift assay for monitoring interaction between Fab RY79-90 and BsRNaseY
Interaction between Fab RY79-90 and BsRNaseY was assessed on a 4% native PAGE gel.
BsRNaseY at fixed concentration (5 µM) was mixed with Fab at concentrations ranging from 0.1 µM to 5 µM in 20 mM HEPES pH 8.0, 100 mM NaCl, 10% glycerol. After 30 min incubation at 20°C, the mixture was loaded on a native gel (prepared with Tris-glycine pH 8.9
and prerun at 4°C in TBE buffer 0.5x at 100 V for 20 min). The migration was performed at 4°C in TBE 0.5x at 150 V for 150 min.
Determination of the dissociation constants for the IgG/BsRNaseY, IgG/Nter-BsRNaseY, and IgG/peptide complexes The K d s were estimated by three independent measurements using a competitive ELISA assay, as described (27) 
Circular dichroism (CD) spectroscopy
The CD spectrum of Nter-BsRNaseY (485 µM in 40 mM MES pH 6.8, 200 mM NaCl) was recorded at 25°C in a 0.01 mm path-length quartz cuve (121.QS, Hellma) over the 185-260 nm spectral range using a JASCO J-810 CD spectropolarimeter equipped with a PFD 423S/L Peltier temperature controller. The spectrum consisted of an average of five consecutive scans acquired at a speed of 50 nm/min, with a time response of 1s for a 1.0 nm band-width. The spectrum was corrected by subtracting the contribution of the buffer measured under the same conditions. Data recorded in mdeg were converted as Δε (M −1 .cm −1 ). Secondary structure estimates were derived from the normalized spectra using the CDSSTR, SELCON3, CONTIN/LL algorithms of the DICHROWEB server or K2D3 (30 , 31) .
Determination of the stoichiometry of the Nter-BsRNaseY/Fab RY79-90 complex by SEC-
MALS
Protein stoichiometry analysis of the Nter-BsRNaseY/Fab RY79-90 complex (at 1:2 ratio) was performed by SEC-MALS using the 'UV extinction from RI peak' method (28) and the protein conjugate method (29) (See Supplementary Methods). In the first method, the UV 280 extinction coefficients of the peaks are extracted from the SEC-MALS data and compared to the predicted extinction coefficients for the complex at different ratios, which are calculated from the amino acid sequence.
SEC-SAXS data collection and analysis
SAXS data on Nter-BsRNaseY were collected on beam line SWING of the SOLEIL synchrotron on a sample eluting from an analytical SEC-column being directly loaded into the SAXS flow-through capillary cell (32) . Nter-BsRNaseY was injected at 20 mg/ml onto a BioSEC3 column (Agilent) equilibrated in 20 mM HEPES pH 7.5, 150 mM NaCl, 5% glycerol.
The flow rate was 200 µl/min, the frame duration 0.75 s and the dead time between frames 0.01 s. The scattering of the elution buffer before void volume was recorded and subtracted from all protein scattering curves. The scattered intensities were displayed on an absolute scale using the scattering by water. The analysis of the full set of SAXS curves measured during the elution was first performed using FOXTROT (32), the SWING in-house software, and then the US-SOMO HPLC module (33) . This program provides for each frame the values of the scattering intensity I(0) and of the radius of gyration R g by applying the Guinier analysis together with a calculation of the approximate molar mass using the Rambo & Tainer approach (34) . Identical frames under the elution peak were finally selected using the CorMap program (35) and averaged for further analysis. The distance distribution function P(r) was calculated from the averaged scattering curve using the GNOM program from the ATSAS suite (36) .
SAXS modelling
In order to obtain an atomic representation of the protein, we submitted the sequence of NterBsRNaseY to the fully automated protein structure homology-modelling server SWISS-MODEL (https://swissmodel.expasy.org/). Interestingly, the program provided a dimer model with a long coiled-coil between residues 61 and 134. The missing N-and C-terminal parts of each monomer were subsequently modeled using DADIMODO (37) (38) , which kept rigid the coiled-coil dimer and refined the position of the terminal parts against SAXS data. This modelling, which was repeated ten times, showed that the N-and C-terminal parts of each monomer are very flexible and that the dimer of Nter-BsRNaseY is able to adopt a great variety of conformations. In these conditions, an approach in terms of conformation ensembles using for example the EOM program (39) would give little additional information and was not explored. 
Crystallization of the
X-Ray Data Collection and Structure Determination
Diffraction data were recorded on PX1 beamline at the SOLEIL synchrotron. Data were processed with XDS (40) ( Table S1 ). Molecular replacement with PHASER (41) using various antibodies of known structure identified antibody Fab13F6-1-2 (PDB code 2QHR) (25) , which belongs to the IgG2a, lx class, as the best model for both the Fv and the CL-CH1 dimer. The atomic model was refined by alternating cycles of model reconstruction with COOT (42) and refinement with BUSTER (43) . The final refinement statistics are given in Table S1 . Figures were drawn with PYMOL. ThrL51 in CDRL2, which lies in the disallowed region of the Ramachandran plot, belongs to a g turn, as commonly observed in all antibody structures.
RESULTS AND DISCUSSION
RY79-90 is an IgG2b, lx antibody induced against a 12-residue conserved peptide of the
RNase Y IDD
After having identified peptides from BsRNaseY most susceptible to be immunogen, six mouse monoclonal antibodies were produced. Among them, one antibody induced against the 12-residue peptide (ERRNELQKQENR) covering residues 79 to 90 was selected for its high affinity for BsRNaseY, as judged by Western-blot analysis (Fig. 1B) , and the fact that it belongs to a conserved region of the IDD of BsRNaseY (Fig. 1A) . The antibody, named RY79-90, has a heavy chain belonging to the IgG2b isotype and utilizes a rare Vlx light chain that is observed in only 0.5% of antibody sequences (44) ( Figure S2 ). The amino acid sequences of Vlx chains are only 30-33% identical to that of other Vl or Vk light chains. They generally display very few somatic mutations (25, 45, 46) and no junctional diversity caused by the rearrangement of the Vlx and Jl2 segments (44) . A characteristic of the Vlx class is that the complementary determining region (CDR) L3, which is entirely encoded by the Vlx gene fragment, is four amino acids longer than in all other antibody light chains ( Figure S2 ). It has been suggested that this unusual light chain confers specificity to the antibodies that contain it (47 Figure S2 ).
Interestingly, the heavy chain isotype distribution of Vlx-bearing antibodies in normal mouse serum, upon immunization with myelin basic protein, showed a bias towards g2a and 2b
isotypes (47) . The heavy chain of Fab RY79-90 belongs also to the IgG2b isotype. VH comes from a combination of the V segment of the Igh-VGAM3.8 VH9 family, a D segment that could not be identified because it is too short and the JH3 segment ( Figure S2 ). There are 10 amino acid mutations compared to the germline gene in the V segment, including one in CDRH1 and two in CDRH2. CDRH3 is exceptionally short, with only three amino acids. 
Nter-BsRNaseY displays a fast equilibrium between monomeric and dimeric forms
The retention volume of a macromolecule on a SEC column depends on its hydrodynamic Methods). Figure 3B shows the evolution during elution of the gyration radius R g and of the molar mass extracted from each SAXS curve. A large plateau is observed for both parameters. and that provide in particular a very good fit to the experimental SAXS curve ( Figure 3C ).
These models, which display a central coiled-coil appended with flexible ends, are only representative but suggest the possible conformation of free Nter-BsRNaseY in solution.
One Fab binds to one Nter-BsRNaseY monomer
The SEC-MALS profile of Fab RY-79-90 displays two main peaks (Table S2 & Figure 2B , black curve). The major species, eluting at 14.7 ml, exhibits a molar mass of 46.0 kDa corresponding to the theoretical mass of the Fab (46.1 kDa). The Nter-BsRNaseY/Fab mixture leads to the appearance of a new peak eluting at 12.1 ml with a molar mass of 69.7 kDa (Table   S2 & Figure 2B , red curve). SEC-MALS data analysis using the "UV extinction from RI peak" method in the ASTRA software (28) 
Overview of the Fab RY79-90 structure
Co-crystallization trials of Fab RY79-90 with Nter-BsRNaseY remained unsuccessful. Yet, the crystal structure of Fab RY79-90 in complex with the inducing peptide was solved at 2.6 Å resolution by molecular replacement using Fab 13F6-1-2 as model (Table S1) All CDRs except L2 contribute to the combining site ( Figure 4A ).
Antibody-peptide interactions
9 out of the 12 residues of the peptide are in contact with the antibody and display clear electron density, whereas electron density was ill-defined for Arg3, Gln9 and Arg12 that were oriented towards the solvent ( Figure 4C ). The high specificity and binding affinity of the antibody/peptide interaction is achieved through numerous side-chain interactions.
Interestingly, despite its very short length, CDRH3 is involved in several main interactions with the peptide, including a bidentate ionic interaction between ArgH94 (CDRH3) and Glu5. Two additional ionic interactions occur between the side chains of AspH52 (CDRH2) and Arg2, and 
Comparison of Fab RY79-90 to Fab 13F6-1-2 and Fv MW1
Considering the rarity of Vlx usage, it is interesting to know whether the other monoclonal antibodies having Vlx light chains share similar antigen specificity. In addition to the structure of Fab reported in this study, two other crystal structures of antibodies Fab or Fv fragments bearing a Vlx light chain have been determined, also in complex with a peptide. The structure of Fab 13F6-1-2, an antibody specific for Ebola viral surface glycoprotein GP was solved in complex with the 11-residue peptide VEQHHRRTDND (25) . Its CDRH3 loop is very long compared to Fab RY79-90, which explains that its peptide binds more on the surface of the combining site compared to the peptide of Fab RY79-90, which is much more buried ( Figure   5A ). Antibody MW1 was directed against a poly-glutamine sequence relevant for Huntington's disease. The structure of Fv MW1 solved in complex with the GQ 10 G peptide, shows that the latter adopts an extended coil-like structure and is also less buried in the antibody combining site than the BsRNaseY peptide (46) ( Figure 5B ).
CONCLUSION
Areas of residual structure in unfolded proteins can be critical to forming the initial site of interaction with a binding partner (57) 
PDB accession numbers
Coordinates and structure factors have been deposited in the Protein Data Bank under accession code 6F7T.
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